

31st July 2019

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Scrip Code: NSE AJANTPHARM EQ
--	--

Re: Outcome of the Board Meeting

Dear Sir/Madam,

At the Board meeting held today, the Board has inter alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2019. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:


- i. Press Release being issued on the Results for the quarter ended 30th June 2019;
- ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2019;
- iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2019;
- iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2019;
- v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2019.

Kindly note that the meeting of the Board of Directors commenced at 2.30 p.m. and concluded at 5:10 p.m. and take the above on your records.

Kindly take the above on your records.

Thanking You,

Yours faithfully,

**GAURANG SHAH**

AVP - Legal & Company Secretary

Encl.: a/a

Press Release**Revenue from operations up 20%**

(1st Quarter, FY 2020 Consolidated Results)

Mumbai, 31st July 2019: Ajanta Pharma Limited, a specialty pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2019.

Q1 FY 2020 performance highlights (compared to Q1 FY 2019)

- Income from operations at Rs. 612 cr. against Rs. 511 cr., up 20%.
- EBITDA at Rs. 168 cr. against Rs. 157 cr., up 7%; EBITDA at 28% of revenue.
- Profit after tax at Rs. 115 cr. against Rs. 106 cr., up 8%, PAT at 19% of revenue.

India

For Q1 FY 2020, India sales was Rs. 194 cr. (against Rs. 178 cr.), up 9%.

As per IMS MAT June 2019, we have posted healthy growth of 18% in Cardiology (segment growth of 12%), 16% in Ophthalmology (segment growth of 10%), 13% in Dermatology (segment growth of 11%) and 18% in Pain Management (segment growth of 10%).

Exports

Q1 FY2020, total export sales were Rs. 404 cr. (against Rs. 324 cr.) posting growth of 25%.

- Emerging Market branded generics sale was Rs. 221 cr. (against Rs.209 cr.) posting 6% growth. Out of which:
 - Africa branded generic sale was Rs. 92 cr. (against Rs. 77 cr.) posting 20% growth.
 - Asia branded generic sale was Rs. 126 cr. (against Rs. 129 cr.) posting 3% de-growth.
- US generic sale was Rs. 102 cr. (against Rs. 61 cr.) posting 67% growth.
- Africa Institution sale was Rs. 81 cr. (against Rs. 54 cr.) posting 50% growth.

In US during Q1 FY 2020, we received 3 ANDA final approval and filed 3 ANDA with US FDA. Out of 30 final approvals, we have commercialised 28 products. 25 ANDAs are awaiting US FDA approval. Company plans to file 10 to 12 ANDAs during this financial year.

R&D

During Q1 FY 2020, R&D expenses were Rs. 40 cr., (Q1 FY 2019 Rs. 41 cr.) which is 7% of operating revenue.

CIN: L24230MH1979PLC022059**Registered Office: 98, Ajanta House, Charkop, Kandivli (West), Mumbai, 400 067, India**

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are first to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centre for formulation development and API is located at Mumbai, having a team of 700+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its consolidated total income growing at 20% CAGR and net profit at 31% CAGR.

For more details visit www.ajantapharma.com. You could also follow us on twitter for regular updates – [www.twitter.com/ajantapharmaLtd](https://twitter.com/ajantapharmaLtd)

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2019

Particulars	3 months ended			₹ in Crore
	30/06/2019	31/03/2019	30/06/2018	Year Ended
	Unaudited	Refer Note 4	Unaudited	Audited
Income				
Revenue from operations	611.94	515.16	510.99	2,055.37
Other income	7.64	1.63	8.13	21.08
Total Income	619.58	516.79	519.12	2,076.45
Expenses				
Cost of materials consumed	124.18	126.82	88.95	391.84
Purchases of stock-in-trade	33.75	11.65	14.25	48.25
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(15.39)	(32.94)	(19.07)	(56.61)
Employee benefits expense	118.32	107.40	104.78	430.71
Finance costs	1.79	0.77	0.17	1.16
Depreciation and amortisation expense	22.78	18.75	17.17	72.08
Other expenses	182.70	175.15	164.59	674.75
Total Expenses	468.13	407.60	370.84	1,562.18
Profit before tax	151.45	109.19	148.28	514.27
Tax Expense				
Current Tax (net)	33.20	13.28	46.39	123.86
Deferred Tax (net)	3.62	7.02	(3.90)	3.44
Profit after tax	114.63	88.89	105.79	386.97
Other Comprehensive Income (OCI)				
Items that will be reclassified subsequently to profit or loss	(0.98)	0.25	(3.19)	(1.95)
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.49)	(0.48)	(0.50)	(1.97)
Income tax relating to items that will not be reclassified to profit or loss	0.17	0.17	0.17	0.69
Other Comprehensive Income for the year, net of tax	(1.30)	(0.06)	(3.52)	(3.23)
Total Comprehensive Income for the period	113.33	88.83	102.27	383.74
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.69	17.54
Other Equity				2,227.67
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	13.14	10.10	12.02	43.97
Diluted - in ₹	13.14	10.10	12.02	43.96

Notes :

- The above results have been reviewed by Audit Committee and approved by Board of Directors at their meeting held on 31 July 2019.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter ended 30 June 2019.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- The figures for the quarter ended March 31, 2019 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter.
- During the quarter, 1,000 equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ 2,000 and securities premium account by ₹ 0.12 crores.
- The Group has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of ₹ 34.97 crores and a corresponding lease liability of ₹ 39.02 crores by adjusting retained earnings by ₹ 2.65 crores (net of deferred tax of ₹ 1.40 crores) as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change, current quarter profit before tax is lower by ₹ 0.05 crores. To this extent, performance for the current period ended 30 June 2019 is not comparable with previous period results.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- The Standalone Financial Results are available on the company's website www.ajantapharma.com.
- Figures for the previous period's have been regrouped, wherever necessary, to correspond with the figures of the current period.



Mumbai, 31 July 2019


By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report

To the Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Ajanta Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:

Ajanta Pharma (Mauritius) Ltd.	Subsidiary
Ajanta Pharma USA Inc.	Subsidiary
Ajanta Pharma Philippines Inc.	Subsidiary
Ajanta Pharma Nigeria Ltd.	Subsidiary
Ajanta Pharma (Mauritius) Intl. Ltd.	Subsidiary

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

gaw

Limited review report (*Continued*)

Ajanta Pharma Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial results of 2 subsidiaries which have not been reviewed, whose interim financial results reflect total revenue of Rs. 55.99 crore, total net profit after tax of Rs. 9.42 crore and total comprehensive income of Rs. 9.42 crore for the quarter ended 30 June 2019, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial statements / financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sreeja Marar

Partner

Mumbai

31 July 2019

Membership No: 111410

UDIN: 19111410AAAABI2533

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2019

Particulars	3 months ended			₹ in Crore
	30/06/2019	31/03/2019	30/06/2018	Year Ended
	Unaudited	Refer Note 3	Unaudited	Audited
Income				
Revenue from operations	545.74	413.53	441.95	1,772.62
Other income	39.62	3.19	69.06	102.15
Total Income	585.36	416.72	511.01	1,874.77
Expenses				
Cost of materials consumed	123.79	126.35	88.21	388.71
Purchases of stock-in-trade	28.63	21.68	14.87	70.79
Changes in inventories of finished goods, work-in-progress and stock-in-trade	11.07	(36.04)	(20.50)	(67.38)
Employee benefits expense	107.37	97.08	95.63	389.37
Finance costs	1.09	0.20	0.11	0.41
Depreciation and amortisation expense	21.71	18.20	16.56	69.90
Other expenses	135.25	137.24	122.77	509.92
Total Expenses	428.91	364.71	317.65	1,361.72
Profit before tax	156.45	52.01	193.36	513.05
Tax Expense				
Current Tax (net)	28.88	8.48	42.37	108.66
Deferred Tax (net)	3.97	2.16	0.17	12.63
Profit after tax	123.60	41.37	150.82	391.76
Other Comprehensive Income (OCI)				
Items that will not be reclassified subsequently to profit or loss	(0.49)	(0.48)	(0.50)	(1.97)
Income tax relating to items that will not be reclassified to profit or loss	0.17	0.17	0.17	0.69
Other Comprehensive Income for the year, net of tax	(0.32)	(0.31)	(0.33)	(1.28)
Total Comprehensive Income for the period	123.28	41.06	150.49	390.48
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.54	17.54	17.69	17.54
Other Equity				2,124.54
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	14.17	4.70	17.14	44.51
Diluted - in ₹	14.16	4.70	17.13	44.51

Notes :


- The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 31 July 2019.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter ended 30 June 2019.
- The figures for the quarter ended March 31, 2019 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter.
- Other income includes :

	3 months ended			Year Ended
	30/06/2019	31/03/2019	30/06/2018	31/03/2019
Dividend from subsidiaries (₹ in Crore)	34.71	-	60.98	77.42

- During the quarter, 1,000 equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ 2,000 and securities premium account by ₹ 0.12 crores.
- The Company has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of ₹ 28.14 crores and a corresponding lease liability of ₹ 31.95 crores by adjusting retained earnings by ₹ 2.48 crores (net of deferred tax of ₹ 1.33 crores) as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change, current quarter profit before tax is lower by ₹ 0.03 crores. To this extent, performance for the current period ended 30 June 2019 is not comparable with previous period results.
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- Figures for the previous period's have been regrouped, wherever necessary, to correspond with the figures of the current period.

By order of the Board
For Ajanta Pharma Ltd.

Yogesh M. Agrawal
Managing Director



Mumbai, 31 July 2019

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report

To the Board of Directors of Ajanta Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Ajanta Pharma Limited for the quarter ended 30 June 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP
Chartered Accountants

Firm's Registration No: 101248W/W-100022


Sreeja Marar
Partner

Mumbai
31 July 2019

Membership No: 111410
UDIN: 19111410AAAABH5012